Discover
ARDX
Ardelyx, Inc.
5.08
1 x 5.00
300 x 5.75
bid
ask
-
0.01
0.20%
350 @ 05:38 PM
5.10 +0.02 (0.33%)
| Ytd | -12.86% | |
| 1y | 14.67% |
5.00
day range
5.09
4.08
52 week range
8.40
| Open | 5.03 | Prev Close | 5.09 | Low | 5.00 | High | 5.09 | Mkt Cap | 1.26B |
| Vol | 2.18M | Avg Vol | 4.03M | EPS | -0.24 | P/E | -23.76 | Forward P/E | 40.65 |
| Beta | 0.60 | Short Ratio | 5.41 | Inst. Own | 70.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 5.76 | 200-d Avg | 6.03 | 1yr Est | 16.30 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-03 | 2026-06 | -0.05 | N/A | N/A | N/A |
| 2026-04-30 | 2026-03 | -0.13 | -0.15 | -0.02 | -15.38% |
| 2026-02-19 | 2025-12 | 0.02 | 0.02 | N/A | N/A |
| 2025-10-30 | 2025-09 | -0.06 | 0 | 0.06 | 93.32% |
| 2025-08-04 | 2025-06 | -0.13 | -0.08 | 0.05 | 38.46% |
| 2025-05-01 | 2025-03 | -0.1 | -0.17 | -0.07 | -70.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-02-23 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-02-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-20 | BTIG | Upgrade | Buy | Buy |
| 2026-01-29 | BTIG | Upgrade | Buy | Buy |
| 2026-01-21 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-01-09 | Citigroup | Upgrade | Buy | Buy |
Profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-15 | BERTRAND WILLIAM C JR | Director | 329.51K | Stock Award(Grant) |
| 2026-05-20 | BISHOP JOHN E | Officer | 336.85K | Sale |
| 2026-05-20 | FOSTER ERIC DUANE | Officer | 417.97K | Sale |
| 2026-05-20 | KELLIHER MICHAEL | Officer | 357.42K | Sale |
| 2026-06-15 | MOTT DAVID M | Director | 3.35M | Stock Award(Grant) |
| 2026-06-14 | RAAB MICHAEL G | Chief Executive Officer | 1.72M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | BlackRock Inc | 21.16M | 0.00 | 8.57% |
| 2025-12-30 | Vanguard Group Inc | 18.98M | 0.00 | 7.68% |
| 2026-03-30 | Millennium Management LLC | 17.84M | 0.00 | 7.22% |
| 2026-03-30 | State Street Corp | 13.60M | 0.00 | 5.51% |
| 2026-03-30 | Vanguard Capital Management, LLC | 10.37M | 0.00 | 4.20% |
| 2026-03-30 | HHG PLC | 8.37M | 0.00 | 3.39% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 7.40M | 0.00 | 3.00% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 7.39M | 0.00 | 2.99% |
| 2026-03-30 | Nomura US Small Cap Core Equity | 6.47M | 0.00 | 2.62% |
| 2026-06-29 | iShares Russell 2000 ETF | 6.40M | 0.00 | 2.59% |
| 2026-05-30 | Nomura Small Cap Core I | 6.27M | 0.00 | 2.54% |
| 2026-06-29 | Vanguard Institutional Extnd Mkt Idx Tr | 2.83M | 0.00 | 1.15% |
Split
| Split | Date |
|---|---|
| 4 : 1 | 2021-07-20 |